Workboat Indexes

Lantern Pharma Inc (NQ: LTRN )

4.520 -0.150 (-3.21%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2024 Add to My Watchlist

Price and Volume

Volume	40,540
Open	4.760
Bid (Size)	4.400 (2)
Ask (Size)	5.190 (1)
Prev. Close	4.670
Today's Range	4.400 - 4.900
52wk Range	2.380 - 11.99
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

June 12, 2024

From Lantern Pharma Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session

May 13, 2024

Via Benzinga

Performance

YTD	+8.39%	+8.39%
1 Month	-25.54%	-25.54%
3 Month	-52.47%	-52.47%
6 Month	+8.39%	+8.39%
1 Year	-17.93%	-17.93%

More News

12 Health Care Stocks Moving In Friday's After-Market Session

May 10, 2024

Via Benzinga

LTRN Stock Earnings: Lantern Pharma Misses EPS for Q1 2024

May 09, 2024

Via InvestorPlace

Recap: Lantern Pharma Q4 Earnings

March 18, 2024

Via Benzinga

Lantern Pharma Earnings Preview

March 15, 2024

Via Benzinga

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

May 09, 2024

From Lantern Pharma Inc.

Via Business Wire

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

May 06, 2024

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

May 02, 2024

From Lantern Pharma Inc.

Via Business Wire

3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire

May 01, 2024

Via InvestorPlace

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

April 24, 2024

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

April 22, 2024

From Lantern Pharma Inc.

Via Business Wire

Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket

April 19, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session

April 11, 2024

Via Benzinga

Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth

April 10, 2024

Via FinancialNewsMedia

AI Sector Stalling: Only 4 Of 7 Categories Went Up In March

March 31, 2024

Via Talk Markets

Six Of Seven AI Stock Categories Increased This Week

March 23, 2024

Via Talk Markets

Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

March 20, 2024

Via FinancialNewsMedia

12 Health Care Stocks Moving In Tuesday's Intraday Session

March 19, 2024

Via Benzinga

LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023

March 18, 2024

Via InvestorPlace

Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

March 20, 2024

From FN Media Group LLC

Via GlobeNewswire

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

March 18, 2024

From Lantern Pharma Inc.

Via Business Wire

Earnings Scheduled For March 18, 2024

March 18, 2024

Via Benzinga

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

March 15, 2024

From Lantern Pharma Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's Intraday Session

March 11, 2024

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.